<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068414</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2020/AJ-01</org_study_id>
    <nct_id>NCT05068414</nct_id>
  </id_info>
  <brief_title>Assessment of the Incidence of Hemorrhagic and Ischemic Events in Post-angioplasty in Anticoagulated Coronary Patients With Atrial Fibrillation</brief_title>
  <acronym>FACOREV</acronym>
  <official_title>Evaluation de l'Incidence Des évènements hémorragiques et ischémiques en Post-angioplastie Chez Des Patients Coronariens anticoagulés Dans le Cadre d'Une Fibrillation Auriculaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated and&#xD;
      fast atrial activity, and coronary artery disease (chronic and acute coronary syndrome) is&#xD;
      characterized by a generally atheromatous narrowing of the coronary arteries. Angioplasty is&#xD;
      necessary to restore arterial circulation in coronary artery disease. A dual anti-aggregating&#xD;
      therapy is then initiated in these patients in parallel with treatment of AF with&#xD;
      anticoagulation. This triple therapy exposes the patient to an increased risk of hemorrhage.&#xD;
      The combination of oral anticoagulation with antiplatelet inhibitor in long-term&#xD;
      anticoagulated patients requiring stent placement has been studied in several recent trials&#xD;
      (e.g. WOEST, PIONEER AF PCI, REDUAL PCI and AUGUSTUS). The results of these studies have&#xD;
      formed the basis of the European recommendations of 2017 and 2020, whereby the therapeutic&#xD;
      strategy depends on the risk of hemorrhage or ischemia. However, the hemorrhagic risk&#xD;
      assessment factors included in the scores overlap with those for ischemic risk. It is&#xD;
      therefore difficult to determine the predominant risk for each patient. Thus, uncertainties&#xD;
      persist as to the optimal duration of a triple therapy and the optimal recommended dose.&#xD;
&#xD;
      In this study, the investigators aim to establish an inventory of the current practices by&#xD;
      evaluating the incidence of hemorrhagic and ischemic events in post-angioplasty in&#xD;
      anticoagulated coronary patients in the context of atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of at least one event from the composite clinical benefit endpoints: death, non-fatal myocardial infarction, ischemic stroke, or major bleeding defined by a Bleeding Academic Research Consortium (BARC) score ≥2</measure>
    <time_frame>Month 12</time_frame>
    <description>Number of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of at least one event from the composite clinical benefit endpoints: death, non-fatal myocardial infarction, ischemic stroke, or major bleeding defined by a Bleeding Academic Research Consortium (BARC) score ≥2</measure>
    <time_frame>Month 1</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of at least one event from the composite clinical benefit endpoints: death, non-fatal myocardial infarction, ischemic stroke, or major bleeding defined by a Bleeding Academic Research Consortium (BARC) score ≥2</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of stent thrombosis</measure>
    <time_frame>Month 1</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of stent thrombosis</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of stent thrombosis</measure>
    <time_frame>Month 12</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of stroke</measure>
    <time_frame>Month 1</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of stroke</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of stroke</measure>
    <time_frame>Month 12</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of myocardial infarction</measure>
    <time_frame>Month 1</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of myocardial infarction</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of myocardial infarction</measure>
    <time_frame>Month 12</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of death from any cause</measure>
    <time_frame>Month 1</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of death from any cause</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of death from any cause</measure>
    <time_frame>Month 12</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of revascularization of the target lesion without death</measure>
    <time_frame>Month 1</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of revascularization of the target lesion without death</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of revascularization of the target lesion without death</measure>
    <time_frame>Month 12</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of peripheral embolism</measure>
    <time_frame>Month 1</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of peripheral embolism</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of peripheral embolism</measure>
    <time_frame>Month 12</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke risk</measure>
    <time_frame>Month 1</time_frame>
    <description>ABCD2 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke risk</measure>
    <time_frame>Month 6</time_frame>
    <description>ABCD2 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke risk</measure>
    <time_frame>Month 12</time_frame>
    <description>ABCD2 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrinsic imputability of transient ischemic attack</measure>
    <time_frame>Month 12</time_frame>
    <description>According to French pharmacovigilance scale from I0 (incompatible) to I4 (very likely)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrinsic imputability of transient ischemic attack</measure>
    <time_frame>Month 12</time_frame>
    <description>According to French pharmacovigilance scale from B0 (Effect appearing quite new after exhaustive research) to B3 (notable effect)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrinsic imputability of hemorrhagic eccent</measure>
    <time_frame>Month 12</time_frame>
    <description>According to French pharmacovigilance scale from I0 (incompatible) to I4 (very likely)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrinsic imputability of hemorrhagic eccent</measure>
    <time_frame>Month 12</time_frame>
    <description>According to French pharmacovigilance scale from B0 (Effect appearing quite new after exhaustive research) to B3 (notable effect)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Academic Research Consortium Score</measure>
    <time_frame>Month 1</time_frame>
    <description>Classified according to subcategories; 1-5; 2-5; or 3-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Academic Research Consortium Score</measure>
    <time_frame>Month 6</time_frame>
    <description>Classified according to subcategories; 1-5; 2-5; or 3-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Academic Research Consortium Score</measure>
    <time_frame>Month 12</time_frame>
    <description>Classified according to subcategories; 1-5; 2-5; or 3-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-platelet aggregations taken</measure>
    <time_frame>Month 1</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-platelet aggregations taken</measure>
    <time_frame>Month 6</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-platelet aggregations taken</measure>
    <time_frame>Month 12</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomical Therapeutic Chemical class of anti-platelet aggregation and the anticoagulants</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomical Therapeutic Chemical class of anti-platelet aggregation and the anticoagulants</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomical Therapeutic Chemical class of anti-platelet aggregation and the anticoagulants</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of triple therapy</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of triple therapy</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of triple therapy</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of anti-platelet aggregation and the anticoagulants</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of anti-platelet aggregation and the anticoagulants</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of anti-platelet aggregation and the anticoagulants</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global drug compliance</measure>
    <time_frame>Month 1</time_frame>
    <description>Girerd score where 0 = good observance, 1/2 = slight observance problems, 3+ = poor observance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global drug compliance</measure>
    <time_frame>Month 6</time_frame>
    <description>Girerd score where 0 = good observance, 1/2 = slight observance problems, 3+ = poor observance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global drug compliance</measure>
    <time_frame>Month 12</time_frame>
    <description>Girerd score where 0 = good observance, 1/2 = slight observance problems, 3+ = poor observance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with antiplatelet and anticoagulant therapy</measure>
    <time_frame>Month 1</time_frame>
    <description>Girerd score specific to anticoagulation/antiplatelet: where 0 = good observance, 1/2 = slight observance problems, 2.5+ = poor observance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with antiplatelet and anticoagulant therapy</measure>
    <time_frame>Month 6</time_frame>
    <description>Girerd score specific to anticoagulation/antiplatelet: where 0 = good observance, 1/2 = slight observance problems, 2.5+ = poor observance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with antiplatelet and anticoagulant therapy</measure>
    <time_frame>Month 12</time_frame>
    <description>Girerd score specific to anticoagulation/antiplatelet: where 0 = good observance, 1/2 = slight observance problems, 2.5+ = poor observance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation test</measure>
    <time_frame>Inclusion</time_frame>
    <description>Kinetic fluorimetry curve, (ST Genesia® analyzer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation test</measure>
    <time_frame>Month 6</time_frame>
    <description>Kinetic fluorimetry curve, (ST Genesia® analyzer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation test</measure>
    <time_frame>Month 12</time_frame>
    <description>Kinetic fluorimetry curve, (ST Genesia® analyzer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual plasma concentration of direct oral anticoagulants (dabigatran, rivaroxaban and apixaban)</measure>
    <time_frame>Inclusion</time_frame>
    <description>Measured with STA-R® Plus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual plasma concentration of direct oral anticoagulants (dabigatran, rivaroxaban and apixaban)</measure>
    <time_frame>Month 6</time_frame>
    <description>Measured with STA-R® Plus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual plasma concentration of direct oral anticoagulants (dabigatran, rivaroxaban and apixaban)</measure>
    <time_frame>Month 12</time_frame>
    <description>Measured with STA-R® Plus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio (INR) for patients under if anti-vitamin K therapy</measure>
    <time_frame>Inclusion</time_frame>
    <description>Measured with STA-R® Plus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio (INR) for patients under if anti-vitamin K therapy</measure>
    <time_frame>Month 6</time_frame>
    <description>Measured with STA-R® Plus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio (INR) for patients under if anti-vitamin K therapy</measure>
    <time_frame>Month 12</time_frame>
    <description>Measured with STA-R® Plus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers level</measure>
    <time_frame>Month 1</time_frame>
    <description>D-Dimer Exclusion assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers level</measure>
    <time_frame>Month 6</time_frame>
    <description>D-Dimer Exclusion assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers level</measure>
    <time_frame>Month 12</time_frame>
    <description>D-Dimer Exclusion assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers level</measure>
    <time_frame>Month 1</time_frame>
    <description>STA-Liatest FM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers level</measure>
    <time_frame>Month 6</time_frame>
    <description>STA-Liatest FM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers level</measure>
    <time_frame>Month 12</time_frame>
    <description>STA-Liatest FM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation test</measure>
    <time_frame>Inclusion</time_frame>
    <description>Platelet inhibition under aspirin and/or P2Y12 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation test</measure>
    <time_frame>Month 6</time_frame>
    <description>Platelet inhibition under aspirin and/or P2Y12 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation test</measure>
    <time_frame>Month 12</time_frame>
    <description>Platelet inhibition under aspirin and/or P2Y12 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between ischemic an/ord hemorrhagic events and adherence to antiplatelet therapy and anticoagulant medication initiated after stent placement</measure>
    <time_frame>Month 12</time_frame>
    <description>Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance rate between the drug compliance score and the biological assessment</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance rate between the drug compliance score and the biological assessment</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance rate between the drug compliance score and the biological assessment</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Thrombosis</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Patients with atrial fibrillation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood panel</intervention_name>
    <description>Thrombin generation test&#xD;
Residual plasma concentration of dabigatran, rivaroxaban and/or apixaban (direct oral anticoagulants)&#xD;
International Normalized Ratio (if anti-vitamin K therapy is prescribed)&#xD;
Platelet aggregation test</description>
    <arm_group_label>Patients with atrial fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at least 18 years of age admitted for hospitalization in the cardiology department&#xD;
        of the Nîmes Hospital for angioplasty as part of an acute or chronic coronary syndrome and&#xD;
        being anticoagulated before or during their hospitalization for a paroxysmal, persistent or&#xD;
        permanent atrial fibrillation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient on anti-coagulating therapy before or during hospitalization for atrial&#xD;
             fibrillation&#xD;
&#xD;
          -  Patient hospitalized in the cardiology ward admitted for acute or chronic coronary&#xD;
             syndrome requiring coronary angioplasty&#xD;
&#xD;
          -  The patient must have given their free and informed consent and signed the consent&#xD;
             form&#xD;
&#xD;
          -  The patient must be a member or beneficiary of a health insurance plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is in a period of exclusion determined by a previous study&#xD;
&#xD;
          -  The patient has already been included into this study&#xD;
&#xD;
          -  It is impossible to give the subject informed information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  Patient pregnant, parturient or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alexia Janes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexia Janes</last_name>
    <phone>04.66.68.36.90</phone>
    <email>Alexia.janes@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Alexia Janes</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit Lattuca</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géralidein Leguelinel-Blache</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marie Knowski</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe Gris</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dual anti-platelet therapy</keyword>
  <keyword>angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

